GlassScriptPhysician profile
Gail H Mautner
NPI 1053353680
$171,043.29
in general payments reported to CMS, 2019-2025
33 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $28K · 2021: $20K · 2022: $18K · 2023: $31K · 2024: $20K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $5,955 · Travel and Lodging: $2,488 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,950.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,775.00 |
| Food and Beverage | $5,954.87 |
| Travel and Lodging | $2,487.93 |
| Education | $216.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $112,276.30 | 2019-2025 | Aklief, Oracea, Epsolay |
| Arcutis Biotherapeutics, INC. | $41,357.75 | 2023-2025 | Zoryve |
| Pfizer INC. | $7,000.53 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $3,150.00 | 2025 | Zoryve |
| Abbvie INC. | $1,733.15 | 2019-2025 | |
| Janssen Biotech, INC. | $764.27 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $583.41 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $525.25 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $453.43 | 2020-2025 | |
| Leo Pharma INC. | $373.06 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $369.25 | 2021-2025 | Opzelura |
| Medimetriks Pharmaceuticals, INC. | $350.00 | 2019 | |
| Amgen INC. | $270.74 | 2020-2025 | Otezla, Otezla |
| Revance Therapeutics, INC. | $235.33 | 2024-2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $212.91 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $205.04 | 2019-2024 | Winlevi, Odomzo, Blu-U |
| Allergan, INC. | $196.53 | 2019-2022 | |
| Merz North America, INC. | $158.74 | 2019 | |
| Botanix Sb INC | $137.69 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $132.36 | 2022-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $114.96 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.84 | 2019-2022 | |
| Celgene Corporation | $75.23 | 2019-2024 | Sotyktu |
| Almirall LLC | $67.65 | 2025 | Klisyri |
| Novartis Pharmaceuticals Corporation | $50.61 | 2021-2023 | |
| Biofrontera INC. | $41.75 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $27.34 | 2022-2023 | Sotyktu |
| Organon LLC | $18.98 | 2025 | Vtama |
| Journey Medical Corporation | $14.97 | 2019 | |
| Ucb, INC. | $14.12 | 2025 | Bimzelx |
| Sebela Pharmaceuticals INC. | $12.32 | 2019 | |
| Epi Health, LLC | $11.79 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Mautner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.